AIkido Pharma Inc. (Form: 8-K, Received: 08/19/2022 17:28:55)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 9, 2022

AIKIDO PHARMA INC.
(Exact name of registrant as specified in its charter)

Delaware	000-05576		52-0849320
(State or other jurisdiction of incorporation)	(Commission File Number)		(IRS Employer Identification No.)

One Rockefeller Plaza, 11th Floor, New York, NY		10020
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code: (703) 993-9325 N/A (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.0001 par value	AIKI	The Nasdaq Capital Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01.

Other Events.

On August 9, 2022, the board of directors (the “Board”) of AIkido Pharma Inc. (the “Company”) received an unsolicited proposal from Shalom Auerbach to acquire all of the outstanding shares of the Company for $8.00 per share in cash.

The Board reviewed and considered Mr. Auerbach’s proposal, and on August 18, 2022, the Company’s counsel delivered a letter to Mr. Auerbach informing him that the Board determined that it was not interested in pursuing the offer.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated:	August 19, 2022	AIKIDO PHARMA INC.

		By:	/s/ Anthony Hayes
		Name:	Anthony Hayes
		Title:	Chief Executive Officer